A5019502646- Dialysis and Renal Disease Management
- Chronic Kidney Disease and Diabetes
- Food Allergy and Anaphylaxis Research
- Lymphoma Diagnosis and Treatment
- Rheumatoid Arthritis Research and Therapies
- Autoimmune and Inflammatory Disorders Research
- Dermatology and Skin Diseases
- Blood Pressure and Hypertension Studies
- Potassium and Related Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Hepatitis C virus research
- Transgenic Plants and Applications
- Acute Kidney Injury Research
- Poisoning and overdose treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Central Venous Catheters and Hemodialysis
- Amino Acid Enzymes and Metabolism
- Sex and Gender in Healthcare
- Diversity and Career in Medicine
- Liver Disease Diagnosis and Treatment
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Drug Transport and Resistance Mechanisms
- Heart Failure Treatment and Management
- Gout, Hyperuricemia, Uric Acid
- Radiopharmaceutical Chemistry and Applications
McMaster University
2019-2024
Impact
2019-2024
Population Health Research Institute
2020-2024
Hamilton Health Sciences
2020-2024
National Kidney Foundation
2023
St. Joseph’s Healthcare Hamilton
2019
Western University
2012-2013
Université de Sherbrooke
2012
St Joseph's Health Care
2012
Southlake Regional Health Center
2012
Key Points In this post hoc analysis of a randomized controlled trial, the proton pump inhibitor pantoprazole led to faster rate eGFR decline as compared with placebo. Additional studies are needed determine effect inhibitors on those at higher risk adverse kidney outcomes. Background Observational have found an association between use and worsening function. It is unclear whether these associations causal. We conducted analyses function using data from Cardiovascular Outcomes for People...
Objective. To determine the factors most strongly associated with an increase in therapy of early rheumatoid arthritis (ERA). Methods. Data from Canadian Early Arthritis Cohort (CATCH) were included if patient had ≥ 2 visits and baseline 6 months data. A regression analysis was done to treatment intensification. Results. Of 1145 patients ERA, 790 met inclusion criteria; mean age 53.4 years (SD 14.7), disease duration 6.1 2.8), 75% female, Disease Activity Score-28 (DAS28) 4.7 1.8) 2.9 at for...
We thank Pabla and Sparreboom for their insightful comments1 highlighting the possibility that excess eGFR decline seen with pantoprazole in our post hoc analysis2 of COMPASS trial could be due to reduced creatinine secretion rather than causing kidney injury. The evidence proton pump inhibitors inhibit organic cation transporter 2 comes primarily from silico vitro experiments,3,4 its existence/magnitude effect is uncertain humans. Additional analyses suggest compared placebo on rate change...
<h3>Background</h3> The disease activity score (DAS) was developed in RA to guide therapy. Its utility practice for ERA has not been fully studied. <h3>Objectives</h3> aim determine factors most strongly associated with an increase therapy at 3 and 6 months. <h3>Methods</h3> Data were collected from Canadian Early Arthritis Cohort (CATCH) patients who included if they had ≥2 visits baseline months data. A regression analysis determined treatment intensification. <h3>Results</h3> Of the 1,145...
Abstract Atopic dermatitis affects millions worldwide and is effectively managed by topical treatments, including calcineurin inhibitors, pimecrolimus tacrolimus. In 2005 2011, the FDA released reviews associating inhibitors with a theoretical cancer risk, albeit an uncertain association. We systematically reviewed risk of in patients atopic exposed to inhibitors. identified randomized controlled trials, comparative, non-comparative non-randomized studies from database inception 6 June 2022,...